Every government is eager to control the increase in expenses by the implementation of central cost containment policies, particularly in relation to pharmaceuticals. For the most part those measures have relied on budgeting or price controls, including negotiated prospective budgets for hospitals,centralized negotiated budgets for ambulatory physicians including drug prescriptions, and limitations on payments for particular medications.Because those traditional central cost containment measures were only partially successful, due to lack of incentives, the health authorities in Europe started to establish incentives for efficient health care delivery.Both traditional and recent containment measures focus especially on the pharmaceutical drugs sector in many countries,as these constitute a health technology that is relatively easy to introduce and implement compared to other forms of care.
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Pricing and reimbursement of new pharmaceuticals have been based until recently on the traditional clinical trial outcomes (efficacy,safety,and quality parameters) used for registration. Now we can distinguish various additional data requirements which relate to the use of the drug in real daily practice. The most important new data requirements are effectiveness,cost-effectiveness,and budgetary impact:
▂ Effectiveness offers a picture of the actual value of a drug in daily practice instead of efficacy, which is examined under ideal conditions in a homogeneous group of patients.
▂ Cost-effectiveness data should permit reliable, reproducible, and verifiable insight into the effectiveness of a drug, the costs that will result from its use, and the possible savings that will be made compared with other drugs and/or treatments. There is currently an increasing demand for health economic data in the decisionmaking process in Europe. Several countries now have formal reporting requirements (United Kingdom, Finland, and Portugal) or will have in the near future (The Netherlands and Norway) [1] . ▂ Budgetary impact data from a financial analysis show the impact of a new drug on the annual national drug budget and total health care budget.
Also other considerations may be taken into account depending on the specific indication, for example, equity in the case of life-style drugs.Although the most evident impact of health economic and budgetary impact studies is expected for central reimbursement audiences, evidence for the use of health economic studies by other audiences is expected to increase (e.g.,patients,hospitals,insurers and formulary committees). A main question is how much the impact is of the various types of data in the pricing and reimbursement process. Although the weight of health economic data has increased in importance in recent years, decision making by the health care authorities is not very transparent. Authorities are hesitant to disclose the rationale for their decisions for both political and technical reasons.Moreover a manufacturer submitting health economic data may claim confidentiality of pricing information and drug profile characteristics to prevent competitors gaining access to this information. As well, most European countries do not have official requirements for submitting health economic data; therefore when it is included in pricing/reimbursement submissions, authorities are not obliged to make public their judgement on health economic data or its weight in the decision-making process. For example, the weight of health economic data and the budgetary impact of a new drug in the decision-making process is not defined. In addition, there are no cutoff points for approving reimbursement for the various data requirements. Health economists may advise on the interpretation of a cost per quality-adjusted life-year, but the decision about how much society will pay for an additional quality-adjusted life-year is political.
The growing burden on manufacturers to submit additional data for their products in the pricing and reimbursement process may have considerable consequences for all players involved, which is complicated by vagueness and uncertainty in the health care decision process. The objective of this manuscript is to present a method for quantifying this type of uncertainty in order to develop a more solid pricing and reimbursement strategy for a new innovative drug. Because the most evident impact of the additional data requirements is expected to be for central reimbursement audiences, we focus on the pricing and reimbursement decision at the central level.The concepts are illustrated for a new hypothetical antidepressant drug in The Netherlands, which was the first country in Europe to have formal health economic guidelines to be used for drug reimbursement applications, although the submission of cost-effectiveness data is still mandatory.
Methods

Background
In The Netherlands the main response to rising costs has been the introduction of an impressive number of government cost-containment policies over the past decade resulting in the Drug Reimbursement System ("GVS"). This system is based on the classification of drugs into groups of "therapeutically interchangeable"drugs with a fixed refund price based on the average list price drugs within the same group (cluster).If a price is set higher than the fixed price, the patient must pay the difference.
When a drug cannot be clustered into an existing group of drugs, a new more expensive drug must show a greater therapeutic value,which is based on a number of clinical properties of a drug, including efficacy and side effects. The decision on reimbursement is based on the value for money of a new drug, which is based on the incremental clinical benefit of the new drug compared with standard therapy. The health authorities make a trade-off between the additional therapeutic value (clinical benefit) and the premium price of the new drug vs.standard therapy.The CFH ("Commissie Pharmaceutische Hulp"),which is a committee of the Dutch Health Insurance Council, evaluates the therapeutic value, cost-effectiveness, and budgetary impact of the new drug and sends a report to the Minister of Public Health, Welfare and Sports (VWS). The minister makes the ultimate decision based on the judgements by the CFH and other specific factors, which are relevant for the new drug (e.g., equity issues).
In the remainder of this paper we assess the pricing potential of a new innovative drug which cannot be clustered in an existing group of drugs. We assume that the reimbursement decision is based only on data on therapeutic value, budgetary impact, and cost-effectiveness, which are taken into consideration by the CHF. The concept is illustrated for a new hypothetical antidepressant drug (AD) which is indicated in depression.The efficacy of this drug is higher than the efficacy of serotonin selective reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), while the side effect profile is similar to that of the SSRIs.Finally,there is no difference in ease of use between the antidepressant drugs.The findings are based on literature,policy reports,and expert opinion of local health policy experts in The Netherlands.
Concept of AHP
A pricing matrix model was developed for the assessment of pricing potential of a new drug. This pricing matrix model is based on the analytic hierarchy process (AHP),which measures decision makers' preferences for the critical success factors. Derived from mathematical psychology and psychometrics, AHP analysis allows an assessment of the importance of product attributes. Price is the main economic attribute of a drug, while efficacy, side effects, application, ease of use, experience, route of administration are examples of clinical product attributes. The AHP is designed to solve complex decision-making problems involving multiple attributes by making judgments about the relative importance of each of the attributes and then to specify a preference for each decision alternative on each attribute.The AHP allows an assessment of the pricing potential of a new drug.When the initial daily treatment costs (DTC) of the new drug in depression (AD) equals the price of standard treatment, the hypothesis is that decision-maker chooses the new drug because of its clinical advantages over standard therapy. Subsequently the price of the new drug increases until the preference switches to standard therapy.In this paper we apply AHP to the pricing and reimbursement process. More detailed information on the theoretical concept of AHP is presented by Saaty [2] .
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Because the assessment of therapeutic value is based on multiple criteria, we must apply AHP initially for the determination of the additional therapeutic value of AD vs. SSRIs and TCAs. The clinical criteria which are relevant for the new antidepressant drug are efficacy,side effects,and experience.The ease of use and route of administration are similar for AD and its comparators (SSRI and TCA) and consequently are not taken into consideration. AHP uses pairwise comparisons to establish priority measures for both the criteria and the decision alternatives. The sets of priorities that need to be determined are as follows:
▂ The priorities of the decision criteria for the assessment of therapeutic value: efficacy, side effects, and experience. ▂ The priorities of the three drugs (AD, SSRI, and TCA) in terms of efficacy. ▂ The priorities of the three drugs (AD, SSRI, and TCA) in terms of side effects. ▂ The priorities of the three drugs (AD, SSRI,and TCA) in terms of experience.
In establishing the priorities for the three drugs in terms of efficacy we assess a preference for the efficacy of the drugs, when the drugs are considered at a time. The AHP employs an underlying scale with values from 1 to 9 to rate the relative preferences between two items:
▂ Extremely preferred: 9 ▂ Very strongly to extremely preferred: 8 ▂ Very strongly preferred: 7 ▂ Strongly to very strongly preferred: 6 ▂ Strongly preferred: 5 ▂ Moderately to strongly preferred: 4 ▂ Moderately preferred: 3 ▂ Equally to moderately preferred: 2 ▂ Equally preferred: 1
Next we develop a pairwise comparison matrix for the ratings for efficacy (⊡ Table 1). The hypothetical response rate for AD was 0.65. We assumed that response rate of 0.65 is moderately preferred to the 0.60 response rate for the SSRIs and TCAs [3] .When AD is three times as preferable as an SSRI (moderately preferred), it follows that an SSRI must be one-third as preferable as AD.Using this logic the other values were obtained by computing the reciprocal value of the existing ratings. Subsequently the relative priorities,of AD vs.SSRIs and TCAs,can be determined by execution of the following steps: (a) summation of the values in each column, (b) dividing of each element of the matrix by its column total, and (c) averaging the elements in each row. This synthesis yields the priority vector for efficacy (Veff), showing that AD has a preference of 0.60, while the SSRIs and TCAs have a preference of only 0.20 (⊡ Table 2 ). Thus AD should be the preferred drug when considering only efficacy. In continuing with the AHP analysis, we determine also the priority vectors for side effects (Vside) and experience (Vexp). The hypothetical side effect profile for AD is similar to that of the SSRIs. Based on the literature we judged that the side effect profile of SSRI is moderately to strongly preferred to that of TCAs (CFH report, 11 July 2000,"GVS-herindeling antidepressiva") [3, 4] .Because of the long experience with SSRIs and TCAs (⊡ Table 1 ) we assumed that the experience of these drugs is very strongly preferred to that of AD (⊡ Table 2 ).
The priorities of the decision criteria (efficacy, side effects, and experience) for the assessment of therapeutic value are listed in ⊡ Table 1 and are based on published information [4] .Subsequently a priority vector for therapeutic value (Vther.) was determined (⊡ Table 2 ).
The final step is to calculate the overall preference of AD for the therapeutic value taking into account the previous priority vectors for efficacy (Veff), side effects (Vside), and experience (Vexp), which are weighted based on the priority vector for therapeutic value (Vther; ⊡ Table 3 ) .This vector shows that AD is the most preferred drug, with a priority of 0.49 followed by the SSRIs (0.33) and TCAs (0.18). This results show that AD has a higher therapeutic value than SSRIs and TCAs.
Reimbursement
Subsequently the AHP analysis of the therapeutic value can be incorporated in the AHP analysis for the reimbursement decision process of AD. The sets of priorities that need to be determined are as follows:
▂ The priorities of the decision criteria for reimbursement: therapeutic value, budgetary impact and cost-effectiveness. ▂ The priorities of the three drugs in terms of therapeutic value ▂ The priorities of the three drugs in terms of budgetary impact ▂ The priorities of the three drugs in terms of cost-effectiveness
The priorities of the decision criteria for reimbursement are listed in ⊡ Table 4 .The initial analysis is based on a price for AD, which equals the DTC of a TCA; the other analyses are based, respectively, on the DTC of an SSRI,and a 10% and 20% higher price than the SSRIs. In the past the Dutch authorities have reimbursed only those significantly more expensive SSRIs which have a greater therapeutic value than TCAs due to a better side effect profile,while the efficacy is similar.Hence we may argue that the Dutch authorities consider therapeutic value more important than the budgetary impact for new drugs in depression. The use of health economic data is only voluntary,and therefore the weight in final decision was considered small. The cost-effectiveness outcomes were based on an existing model, which was adjusted to AD [3] . Subsequently the priority vectors presented in ⊡ Table 5 were determined for the initial analysis. These figures shows that AD is the most preferred drug,with a priority of 0.49 followed by the TCAs (0.26) and SSRIs (0.25), when AD is priced as a TCA. The similar preference for SSRIs and TCAs shows that authorities are indeed willing to pay the additional price for SSRIs in order to reduce the side effects (⊡ Table 6 ).
We performed additional scenario analysis on the price of AD (⊡ Table 7 ). The results show that a premium price can be charged, which is 10% higher than the DTC of SSRIs: AD is still the most preferred drug, with a priority of 0.37.When the DTC of AD exceed 20% of the SSRI price,AD is no longer the most preferred drug.Thus this analysis shows that the 5% increase in response of AD compared with SSRIs and TCAs may justify a price premium up to 20% over the SSRI price, and that AD will probably not be reimbursed at a higher price.
Discussion
We present a method to assess the pricing potential of a new AD taking into consideration the various data requirements in the reimbursement process. This pricing matrix model is based on the AHP concept which can quantify the uncertainty associated with the decision making process for the reimbursement of new Table 7 Scenario analysis for the DTC of AD pharmaceuticals. The concepts are illustrated for a new AD in The Netherlands. The efficacy of this drug was found to be higher than that efficacy of SSRIs and TCAs (0.65% vs. 0.60% response), while the side effect profile was similar to that of the SSRIs. The results of this AHP analysis show that the superior efficacy of AD may justify a price premium up to 20% over the SSRI price to the reimbursement authorities.
There are a number of methodological considerations which need to be addressed.At the moment health economic data are only voluntary in The Netherlands.Therefore the weight of health economic data was much lower than that of therapeutic value and budgetary impact. However, in 2005 the weight of the health economic data will increase when costeffectiveness data become an official requirement in The Netherlands.The weight of the various data may also depend on disease severity.The additional therapeutic value may have a higher weight in more severe diseases than depression. This means that health care authorities are willing to accept a higher budgetary impact in severe diseases. For example, the Dutch authorities have reimbursed new innovative drugs with a substantial impact on the drug budget, while the health care community does not seem convinced of the additional therapeutic value of those drugs,for example,interferons in multiple sclerosis.
The weight (priority vectors) may also be rather different when the analysis is performed for other target audiences than the central authorities.For example,local health authorities (insurers) may give more weight to the budgetary impact analysis, leading to different priority vectors. Alternatively, the physician will accept a higher price for a new drug than a pharmacist with direct budget responsibility.
This analysis is based only on the formal decision criteria (therapeutic value, budgetary impact,and cost-effectiveness) while in reality political criteria (e.g., equity) may also influence the final decision by the health authorities.These other criteria may change the weight (priority vectors), for example, a successful lobby by a patient society may positively increase the weight of therapeutic value vs.budgetary impact and thus facilitating reimbursement.On the other hand,the off-label risk may increase the weight of budgetary impact vs. therapeutic value, which would reduce the probability of reimbursement.
A key step in the AHP is the establishment of priorities through the use of pairwise comparisons.An important consideration in terms of the quality of the ultimate decision relates to the consistency of judgments that the decision maker demonstrated during the series of pairwise comparisons. The AHP provides a measure of consistency of the pairwise comparisons.A comparison,which yields a consistency ratio below 0.10, is considered consistent. In the pairwise comparisons in this analysis the consistency ratios for all vectors were smaller than 0.10,and consequently the results can be considered reliable. The details on the mathematical computation can be found in the original paper on AHP [2] .The consistency analyses showed that the underlying assumptions and relationships were not contradictory, which prevents erroneous strategic pricing decisions.
The use of the matrix approach depends heavily on the preference ratings for the various product attributes. These preferences may be derived from literature or expert opinion.When preferences are derived from the literature, there is the potential for bias in the interpretation of the data by the researcher. Alternatively, the preferences may be derived from experts, ideally decision makers. However, they may also yield biased estimates of the preferences, for example, an overestimation of budgetary impact and underestimation of clinical benefit,which would reduce the pricing potential. However, one may argue that this type of bias should be incorporated in the model because it is probably a reflection of the real health care policy environment, where the decision makers' main goal is to minimize expenditures.A more practical constraint is that health care decision makers are not willing to participate in a survey for a pricing study. Hence in practice we would suggest replacing the official decision makers by health care policy experts, especially those with experience in pharmaceuticals, who could act as substitutes and would be able to predict the estimates by the decision maker, based on their experience in this area. There may be uncertainty associated with the estimates of the experts.On the one hand, the above consistency measure allows an assessment of a specific type of uncertainty related to contradictory estimations. On the other hand, the uncertainty in variance of the estimates can be reduced by using an appropriate number of experts.
Finally,the current analysis based only on the reference system for reimbursement; we did not consider the pricing law. The maximum price in The Netherlands is constrained by this law, which means that the maximum price depends on the average price of a drug in the neighboring countries of The Netherlands: Germany, Belgium, United Kingdom, and France. Hence the price for AD resulting from the AHP analysis may be adjusted downwards when the price law is taken into consideration.
The conclusion is that the AHP concept may be applied to the pricing and reimbursement environment, and that it may be used for an assessment of the pricing potential of a new drug. Further research is required to explore in more detail the methodological considerations which we address. Table 3 shown on page 10 of the version published online has excluded (by typographical error) the regression findings for DRG E 62A in one row, which should read as follows: CostPP=6950 (β 0 ) -70 (Age) +14070 (Outlier) +1440 (Procedures) + E
